| abstract |
There is provided a method for screening a substance capable of inhibiting cell death induced by the activation of PARP, particularly a substance which is useful as a therapeutic agent and/or a preventive agent for rheumatoid arthritis, neuronal death at the time of cerebral ischemia, cell death of the heart after myocardial infarction reperfusion, autoimmune destruction of β-cells of pancreatic islets of Langerhans, cell death after shock, or inflammatory reaction by immunocyte death. Also provided are a novel protein and a novel gene coding for the same. n The aforementioned screening method comprises a step of allowing a substance to be tested to contact with a cell expressing an LTRPC2 protein under such a condition that the LTRPC2 protein can be activated, and a step of analyzing inhibition of the activation of the LTRPC2 protein. The aforementioned novel protein is a rat or mouse LTRPC2 protein, and the aforementioned novel gene is a rat or mouse LTRPC2 gene. |